Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A2 | O00482 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ILK | Q13418 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6302848 | 0.92 | KDM1A (0.44) | NR5A2KDM1ASIGMAR1SMN1; SMN2KEAP1 | |
| SCHEMBL6304851 | 0.86 | ALDH1A1 (0.40) | NR5A2SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL6302885 | 0.86 | ALDH1A1 (0.40) | SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL6533138 | 0.84 | ALOX15 (0.41) | SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL18235472 | 0.83 | LMNA (0.42) | KDM1ASIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL18235388 | 0.81 | KDM1A (0.42) | KDM1ASIGMAR1SMN1; SMN2POLBMEN1 | |
| SCHEMBL15553829 | 0.81 | KDM1A (0.42) | KDM1ASIGMAR1SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL18235299 | 0.81 | ALDH1A1 (0.39) | SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL10247439 | 0.79 | HTR2A (0.51) | NR5A2KDM1ASIGMAR1POLBMAPK10 | |
| SCHEMBL28811813 | 0.79 | NR5A2 (0.45) | NR5A2KDM1ASIGMAR1POLBMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332905-A | (S) -N-phenyl-1- (pyridin-2-yl) pyrrolidine-2-carboxamide derivatives | 上海翊石医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2023-01-12 | — | — | US | disclosed |
| CN-114340734-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-10414769-B2 | 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-09-17 | — | — | US | disclosed |
| US-20180141948-A1 | NEW 5,8-DIMETHYL-9-PHENYL-5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLIN-2-YL)-(1H-PYRAZOL-3-YL)-AMINES AND DERIVATIVES AS IGF-1R/IR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-24 | — | — | US | disclosed |
| US-20180141948-A1 | NEW 5,8-DIMETHYL-9-PHENYL-5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLIN-2-YL)-(1H-PYRAZOL-3-YL)-AMINES AND DERIVATIVES AS IGF-1R/IR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-24 | — | — | US | disclosed |
| WO-2016180843-A1 | NEW 5,8-DIMETHYL-9-PHENYL-5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLIN-2- YL)-(1 H-PYRAZOL-3-YL)-AMINES AND DERIVATIVES AS IGF-1 R/IR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-17 | — | — | WO | disclosed |
| WO-2014112799-A1 | PHENOXYBENZAMIDE GLUCOKINASE ACTIVATOR CONTAINING NOVEL HETEROARYL AND METHOD FOR PREPARING SAME | 주식회사유한양행 (KR) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014003483-A1 | FUSED PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON FMS KINASES | HANMI PHARM. CO., LTD. (KR) | 2014-01-03 | — | — | WO | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414769-B2 | 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors | IGF1R, IGFBP1, INSR | NR5A2 87/4885KDM1A 887/4885SIGMAR1 929/4885 |
| US-20180141948-A1 | NEW 5,8-DIMETHYL-9-PHENYL-5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLIN-2-YL)-(1H-PYRAZOL-3-YL)-AMINES AND DERIVATIVES AS IGF-1R/IR INHIBITORS | IGF1R, IGFBP1, IRS1 | NR5A2 77/4885KDM1A 877/4885SIGMAR1 568/4885 |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP4K2, MAP4K4 | NR5A2 1871/4885KDM1A 1786/4885SIGMAR1 1700/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | NR5A2 2791/4885KDM1A 307/4885SIGMAR1 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.